{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:08:01Z","timestamp":1773972481504,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013840","name":"Biocenter Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Heart Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005609","name":"Turun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022793","name":"Turku University Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117453","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:08:45Z","timestamp":1727377725000},"page":"117453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression"],"prefix":"10.1016","volume":"180","author":[{"given":"R.","family":"Huttunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"Haapanen-Saaristo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hjelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jokilammi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Paatero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"J\u00e4rvel\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.biopha.2024.117453_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.biopha.2024.117453_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061470","article-title":"SGLT2 Inhibitors in type 2 diabetes mellitus and heart failure-a concise review","volume":"11","author":"Keller","year":"2022","journal-title":"J. Clin. Med"},{"issue":"22","key":"10.1016\/j.biopha.2024.117453_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"E.-R.O. Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.117453_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS program (Canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.biopha.2024.117453_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"D.T. Investigators, Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"23","key":"10.1016\/j.biopha.2024.117453_bib6","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and Etstablished atherosclerotic cardiovascular disease: Results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.biopha.2024.117453_bib7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"E.-R.T. Investigators, Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2024.117453_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116650","article-title":"Cardiovascular outcomes and molecular targets for the cardiac effects of sodium-glucose cotransporter 2 inhibitors: a systematic review","volume":"175","author":"Madonna","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2024.117453_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379765","article-title":"Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis","volume":"11","author":"Lan","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"Eur. J. Heart Fail"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"S.-W.T. Investigators, Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.biopha.2024.117453_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: dupporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.117453_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.117453_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10741-020-10041-1","article-title":"Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure","volume":"26","author":"Dutka","year":"2021","journal-title":"Heart Fail Rev."},{"issue":"5","key":"10.1016\/j.biopha.2024.117453_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure-has the mystery neen unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr. Heart Fail Rep."},{"issue":"16","key":"10.1016\/j.biopha.2024.117453_bib17","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.biopha.2024.117453_bib18","article-title":"Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: a meta-analysis of clinical studies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2024.117453_bib19","article-title":"SGLT2 inhibitors: how do they affect the cardiac cells","author":"Erdogan","year":"2024","journal-title":"Mol. Cell Biochem"},{"issue":"11","key":"10.1016\/j.biopha.2024.117453_bib20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s44161-023-00352-5","article-title":"Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure","volume":"2","author":"Angermann","year":"2023","journal-title":"Nat. Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"issue":"1","key":"10.1016\/j.biopha.2024.117453_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96033-z","article-title":"Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia","volume":"11","author":"Heliste","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117453_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113882","article-title":"Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos","volume":"156","author":"Huttunen","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2024.117453_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-61779-523-7_2","article-title":"Quantifying cardiac functions in embryonic and adult zebrafish","author":"Hoage","year":"2012","journal-title":"Methods Mol. Biol. 843"},{"issue":"1","key":"10.1016\/j.biopha.2024.117453_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. Roy. Stat. Soc. Ser. B"},{"issue":"11","key":"10.1016\/j.biopha.2024.117453_bib26","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion--from mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2024.117453_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.freeradbiomed.2021.01.036","article-title":"Energy substrate metabolism and mitochondrial oxidative stress in cardiac ischemia\/reperfusion injury","volume":"165","author":"Dambrova","year":"2021","journal-title":"Free Radic. Biol. Med"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/zeb.2007.0508","article-title":"A rapid apoptosis assay measuring relative acridine orange fluorescence in zebrafish embryos","volume":"4","author":"Tucker","year":"2007","journal-title":"Zebrafish"},{"key":"10.1016\/j.biopha.2024.117453_bib29","first-page":"5732956","article-title":"The role of oxidative stress in cardiac disease: from physiological response to injury factor","author":"Oria","year":"2020","journal-title":"Oxid. Med Cell Longev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.24","article-title":"Using monochlorobimane to visualize glutathione utilization in the developing zebrafish (Danio rerio) embryo","volume":"1","author":"Rastogi","year":"2021","journal-title":"Curr. Protoc."},{"issue":"16","key":"10.1016\/j.biopha.2024.117453_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"E.-P.T. Investigators, Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.biopha.2024.117453_bib32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2024.117453_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.biopha.2024.117453_bib34","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/CIRCRESAHA.122.320396","article-title":"Zebrafish Models of Cardiac Disease: From Fortuitous Mutants to Precision Medicine","volume":"130","author":"Gonz\u00e1lez-Rosa","year":"2022","journal-title":"Circ. Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.117453_bib35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/bj2551057","article-title":"Is vitellogenin an ancestor of apolipoprotein B-100 of human low-density lipoprotein and human lipoprotein lipase?","volume":"255","author":"Baker","year":"1988","journal-title":"Biochem J."},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0008-6363(00)00029-8","article-title":"J.W. Bryant, Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat","volume":"46","author":"Peterson","year":"2000","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.biopha.2024.117453_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/01.RES.0000013290.12884.A3","article-title":"Matrix metalloproteinases: regulation and dysregulation in the failing heart","volume":"90","author":"Spinale","year":"2002","journal-title":"Circ. Res"},{"issue":"24","key":"10.1016\/j.biopha.2024.117453_bib38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.111.066787","article-title":"\u03b2-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells","volume":"125","author":"Jaffr\u00e9","year":"2012","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117453_bib39","first-page":"S2033","article-title":"Effects of hydrogen sulfide on myocardial fibrosis in diabetic rats: changes in matrix metalloproteinases parameters","volume":"26","author":"Xiao","year":"2015","journal-title":"Biomed. Mater. Eng."},{"issue":"3","key":"10.1016\/j.biopha.2024.117453_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41419-018-0425-0","article-title":"Hypoxia-Induced Matrix Metalloproteinase-13 Expression in Exosomes from Nasopharyngeal Carcinoma Enhances Metastases","volume":"9","author":"Shan","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2024.117453_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12013-023-01205-5","article-title":"Hypoxia Potentiated Lung Cancer Cell Migration and Invasion by up-regulating HIF1\u03b1\/JAK2\/STAT3 Axis and Activating MMP13 Transcription","volume":"82","author":"Cheng","year":"2024","journal-title":"Cell Biochem Biophys."},{"key":"10.1016\/j.biopha.2024.117453_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.995216","article-title":"Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db\/db mice","volume":"9","author":"Tu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.biopha.2024.117453_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122354","article-title":"Empagliflozin protects against isoprenaline-induced fibrosis in rat heart through modulation of TGF-\u03b2\/SMAD pathway","volume":"337","author":"Elsayed","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.117453_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175194","article-title":"Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure","volume":"931","author":"Shiraki","year":"2022","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.017483","article-title":"Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model","volume":"10","author":"Nishinarita","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.biopha.2024.117453_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12916-022-02485-z","article-title":"Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling","volume":"20","author":"Lee","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.biopha.2024.117453_bib47","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"EMPEROR Committees and Investigators, Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur. J. Heart Fail"},{"issue":"4","key":"10.1016\/j.biopha.2024.117453_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.015298","article-title":"Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ. Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.biopha.2024.117453_bib49","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/01.CIR.98.21.2334","article-title":"Sudden cardiac death","volume":"98","author":"Zipes","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2024.117453_bib50","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J. Cardiovasc Electro"},{"issue":"2","key":"10.1016\/j.biopha.2024.117453_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell Biochem"},{"issue":"3","key":"10.1016\/j.biopha.2024.117453_bib52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224013398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:15:13Z","timestamp":1773969313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224013398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"alternative-id":["S0753332224013398"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117453","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117453"}}